Abstract | OBJECTIVE:
Tibolone has been shown to alleviate climacteric symptoms. This study was designed to compare the effect of tibolone ( Livial, 2.5 mg daily) on different climacteric complaints and its impact on the endometrium, determined by vaginal ultrasound, with that of conjugated estrogens ( Premarin, 0.625 mg daily) continuously for 6 months in combination with the progestogen medrogestone (Colpron, 2 x 5 mg daily for 12 days each month). METHODS: One hundred and twenty-nine postmenopausal women were recruited and the severity of climacteric symptoms as well as endometrial thickness were recorded at the pre-trial examination and after 1, 3, and 6 months. RESULTS: With the exception of vertigo, mood depression, mood disorder, loss of libido, and dryness of skin, where tibolone was found to be more effective than conjugated estrogens/ medrogestone, climacteric symptoms improved significantly in both groups over the 6-month study period. Endometrial thickness did not increase significantly in the tibolone group, whereas in the conjugated estrogens/ medrogestone group there was a highly significant increase after 1 month and still a trend towards significance after 6 months. Recurrence of vaginal bleeding occurred significantly less frequently in the tibolone group than in the comparison group. CONCLUSION:
|
Authors | C Egarter, J Huber, R Leikermoser, R Haidbauer, H Pusch, F Fischl, M Putz |
Journal | Maturitas
(Maturitas)
Vol. 23
Issue 1
Pg. 55-62
(Feb 1996)
ISSN: 0378-5122 [Print] Ireland |
PMID | 8861087
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Estrogens
- Norpregnenes
- Progestins
- tibolone
|
Topics |
- Climacteric
(drug effects, physiology)
- Dose-Response Relationship, Drug
- Endometrium
(anatomy & histology, diagnostic imaging, drug effects)
- Estrogens
(adverse effects, standards, therapeutic use)
- Female
- Humans
- Incidence
- Middle Aged
- Norpregnenes
(adverse effects, standards, therapeutic use)
- Progestins
(adverse effects, standards, therapeutic use)
- Surveys and Questionnaires
- Time Factors
- Ultrasonography
- Uterine Hemorrhage
(drug therapy, epidemiology)
|